Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events

ME Staff 8-k
-
0

Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Other Events
Item 8.01. Other Events.

In January2018, Momenta announced the initiation of a strategic review of its business including, but not limited to, evaluating options for new partnerships across the Company’s portfolio, additional cost reduction strategies, and the sale of certain assets such as M923.The Company subsequently set a goal to complete the strategic review by the end of the second quarter of 2018. At this time, the strategic review is progressing, but is not yet complete and the Company plans to provide an update on the strategic review either before, or at the same time as, the Company reports its second quarter 2018 financial results.


About Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.